• Publications
  • Influence
Clinical Consequences of Cytochrome P450 2C9 Polymorphisms
Present knowledge about the pharmacokinetics, drug responses, and outcomes of clinical studies in individuals with different CYP2C9 genotypes is summarized. Expand
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
Combinations of polymorphisms in pharmacokinetic and pharmacodynamic pathways of relevance might contribute to identify genotypes associated with best and worst responders and they may also identify susceptibility to adverse drug reactions. Expand
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication
CYP2D6 genotypes predicting ultrarapid metabolism resulted in about 50% higher plasma concentrations of morphine and its glucuronides compared with the EM, and it might be good if physicians would know about the CYP2D 6 duplication genotype of their patients before administering codeine. Expand
Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs
Pharmacogenetic variability plays an important role in the pharmacokinetics of oral antidiabetic drugs; however, to date, the impact of this variability on clinical outcomes in patients is mostly unknown and prospective studies on the medical benefit of CYP genotyping are required. Expand
The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease
The data show that rs75932628 is highly significantly associated with the risk of AD across 24,086 AD cases and 148,993 controls of European descent and carriers of the rs75 932628 risk allele showed significantly increased levels of CSF‐total‐tau but not Aβ42 suggesting that TREM2's role in AD may involve tau dysfunction. Expand
CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages
This review aimed to provide distinct dose recommendations for antidepressants based on the genotypes of cytochrome P450 enzymes CYP2D6 and CYP1C19 to provide a useful complementation to clinical monitoring and therapeutic drug monitoring. Expand
Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
Tolbutamide was confirmed as a substrate of the genetically polymorphic enzyme CYP2C9, and the pronounced differences in pharmacokinetics due to the amino acid variants did not significantly affect plasma insulin and glucose concentrations in healthy volunteers. Expand
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
Bupropion is applied in depression and smoking cessation. Genetic polymorphisms in cytochrome P450 2B6 (CYP2B6) may cause variability in bupropion pharmacokinetics since hydroxylation is known to beExpand
Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2
According to in vitro data, the polymorphic cytochrome P450 enzyme 2C9 (CYP2C9) may be the major S‐ibuprofen hydroxylase. In humans, there are 2 variants of CYP2C9 with a high population frequency.Expand
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype
The role of the CYP2C8*3 allele coding for the Arg139Lys and Lys399Arg amino acid substitutions is clarified with regard to the pharmacokinetics and clinical effects of rosiglitazone. Expand